Therapeutic Potency of Cord Blood Stem Cells in Patients with Cerebral Palsy: A Systemic Literature Review

Authors

1 Neonatal Research Center, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Qaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of Oncology and Stem Cell, Mashhad University of Medical Sciences, Mashhad, Iran. .

Abstract

Background: The main objective of this study was to systematically review the reported potency of cord blood stem cells in treating patients with neurological disorders such as cerebral palsy. 
Methods: PubMed, Scopus, and Cochrane were searched thoroughly on September 2016 using the following search terms: “Umbilical cord blood stem cells” AND “development” AND “cerebral palsy” to find articles in which the umbilical cord blood stem cells were used to treat patients with cerebral palsy. Only English-language studies conducted on patients with cerebral palsy were included and used for data extraction. 
Results: Of a total of 77 articles found in the database search, only 6 papers fully met the inclusion criteria. The results showed successful treatment with cord blood stem cells in 165 patients with cerebral palsy.
Conclusion: Studies on both human and animal models have shown the beneficial effects of stem cell therapy in the treatment of various neurological diseases. Data presented that cord blood stem cells can be considered as a main therapeutic strategy to treat patients with cerebral palsy. In addition, it is shown that cord blood stem cells significantly improve motor function, cognition, and memory in patients with cerebral palsy.

Keywords


1. Pfeifer LI, Silva DB, Funayama CA, Santos JL. Classification of cerebral palsy: association between gender, age, motor type, topography and Gross Motor Function. Arq Neuropsiquiatr. 2009; 67(4):1057-61.

2. Madigan RR, Wallace SL. Scoliosis in the institutionalized cerebral palsy population. Spine. 1981; 6(6):583-90.

3. Kirby RS, Wingate MS, Van Naarden Braun K, Doernberg NS, Arneson CL, Benedict RE, et al. Prevalence and functioning of children with cerebral palsy in four areas of the United States in 2006: a report from the Autism and Developmental Disabilities Monitoring Network. Res Dev Disabil. 2011; 32(2):462-9.

 4. Ashwal S, Russman BS, Blasco PA, Miller G, Sandler A, Shevell M, et al. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2004; 62(6):851-63.

5. Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010; 74(4):336-43.

 6. Sakzewski L, Ziviani J, Boyd R. Systematic review and meta-analysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics. 2009; 123(6):e1111-22.

7. Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil. 2006; 28(4):183-91.

 8. Ruff CA, Faulkner SD, Fehlings MG. The potential for stem cell therapies to have an impact on cerebral palsy: opportunities and limitations. Dev Med Child Neurol. 2013; 55(8):689-97.

 9. Forraz N, McGuckin CP. The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine. Cell Prolif. 2011; 44(Suppl 1):60-9.

10. Kurtzberg J. Update on umbilical cord blood transplantation. Curr Opin Pediatr. 2009; 21(1): 22-9. 11. Ali H, Bahbahani H. Umbilical cord blood stem cellspotential therapeutic tool for neural injuries and disorders. Acta Neurobiol Exp. 2010; 70(3):316-24.

 12. Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS, et al. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells. 2013; 31(3):581-91.

13. Crompton KE, Elwood N, Kirkland M, Clark P, Novak I, Reddihough D. Feasibility of trialling cord blood stem cell treatments for cerebral palsy in Australia. J Paediatr Child Health. 2014; 50(7):540-4. 14. Papadopoulos KI, Low SS, Aw TC, Chantarojanasiri T. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor Neurol Neurosci. 2011; 29(1):17-22.

 15. Lee YH, Choi KV, Moon JH, Jun HJ, Kang HR, Oh SI, et al. Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy. J Transl Med. 2012; 10:58.

16. Kang M, Min K, Jang J, Kim SC, Kang MS, Jang SJ, et al. Involvement of immune responses in the efficacy of cord blood cell therapy for cerebral palsy. Stem Cell Dev. 2015; 24(19):2259-68.

 17. Wang X, Hu H, Hua R, Yang J, Zheng P, Niu X, et al. Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors. Cytotherapy. 2015; 17(2): 224-31.

18. Shroff G, Gupta A, Barthakur JK. Therapeutic potential of human embryonic stem cell transplantation in patients with cerebral palsy. J Transl Med. 2014; 12(1):318.

19. Carroll JE, Mays RW. Update on stem cell therapy for cerebral palsy. Expert Opin Biol Ther. 2011; 11(4):463-71.

20. Castillo-Melendez M, Yawno T, Jenkin G, Miller SL. Stem cell therapy to protect and repair the developing brain: a review of mechanisms of action of cord blood and amnion epithelial derived cells. Front Neurosci. 2013; 7:194.

21. Tsuji M, Taguchi A, Ohshima M, Kasahara Y, Sato Y, Tsuda H, et al. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience. 2014; 263:148-58.

 22. Wang F, Maeda N, Yasuhara T, Kameda M, Tsuru E, Yamashita T, et al. The therapeutic potential of human umbilical cord blood transplantation for neonatal hypoxic-ischemic brain injury and ischemic stroke. Acta Med Okayama. 2012; 66(6):429-34.

 23. Ali H, Bahbahani H. Umbilical cord blood stem cells - potential the rapeutic tool for neural injuries and disorders. Acta Neurobiol. 2010; 70(3):316-24.

 24. Berry MF, Engler AJ, Woo YJ, Pirolli TJ, Bish LT, Jayasankar V, et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Amer J Physiol Heart Circul Physiol. 2006; 290(6):H2196-203.

25. Kitada M, Dezawa M. Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinsons Dis. 2012; 2012:873706.

26. Hermann A, List C, Habisch HJ, Vukicevic V, EhrhartBornstein M, Brenner R, et al. Age-dependent neuroectodermal differentiation capacity of human mesenchymal stromal cells: limitations for autologous cell replacement strategies. Cytotherapy. 2010; 12(1):17-30.

 27. Zilka N, Zilkova M, Kazmerova Z, Sarissky M, Cigankova V, Novak M. Mesenchymal stem cells rescue the Alzheimer's disease cell model from cell death induced by misfolded truncated tau. Neuroscience. 2011; 193:330-7.

28. Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant. 2007; 40(7):609-19.